Guardant Health Valuation
Is GH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GH * (MX$672) is trading above our estimate of fair value (MX$522.56)
Significantly Below Fair Value: GH * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GH *?
Key metric: As GH * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GH *'s PS Ratio? | |
|---|---|
| PS Ratio | 5.8x |
| Sales | US$692.26m |
| Market Cap | US$4.03b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.4x |
| Enterprise Value/EBITDA | -11.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GH *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.2x | ||
BTSG BrightSpring Health Services | 0.3x | 9.1% | US$3.3b |
LFST LifeStance Health Group | 2.3x | 12.2% | US$2.8b |
OPCH Option Care Health | 0.8x | 7.4% | US$3.8b |
PRVA Privia Health Group | 1.5x | 11.2% | US$2.5b |
GH * Guardant Health | 5.8x | 17.0% | Mex$4.0b |
Price-To-Sales vs Peers: GH * is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (1.2x).
Price to Sales Ratio vs Industry
How does GH *'s PS Ratio compare vs other companies in the South American Healthcare Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: GH * is expensive based on its Price-To-Sales Ratio (5.8x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is GH *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GH *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$672.00 | Mex$873.57 +30.0% | 13.6% | Mex$1,218.93 | Mex$690.73 | n/a | 20 |
| Nov ’25 | n/a | Mex$832.67 0% | 12.7% | Mex$1,000.80 | Mex$640.51 | n/a | 20 |
| Oct ’25 | n/a | Mex$825.48 0% | 14.1% | Mex$1,159.93 | Mex$657.29 | n/a | 20 |
| Sep ’25 | n/a | Mex$825.48 0% | 14.1% | Mex$1,159.93 | Mex$657.29 | n/a | 20 |
| Aug ’25 | Mex$591.47 | Mex$728.12 +23.1% | 17.1% | Mex$931.10 | Mex$521.42 | n/a | 20 |
| Jul ’25 | n/a | Mex$685.17 0% | 18.7% | Mex$859.89 | Mex$512.27 | n/a | 20 |
| Jun ’25 | n/a | Mex$628.59 0% | 19.9% | Mex$790.17 | Mex$470.74 | n/a | 18 |
| May ’25 | n/a | Mex$661.89 0% | 21.3% | Mex$851.00 | Mex$459.54 | n/a | 18 |
| Apr ’25 | Mex$293.83 | Mex$686.30 +133.6% | 20.7% | Mex$901.47 | Mex$450.73 | n/a | 18 |
| Mar ’25 | Mex$360.00 | Mex$709.41 +97.1% | 19.4% | Mex$923.08 | Mex$461.54 | n/a | 18 |
| Feb ’25 | n/a | Mex$796.06 0% | 18.5% | Mex$1,033.35 | Mex$465.01 | n/a | 18 |
| Jan ’25 | n/a | Mex$806.05 0% | 18.9% | Mex$1,092.44 | Mex$460.87 | n/a | 18 |
| Dec ’24 | n/a | Mex$848.36 0% | 18.8% | Mex$1,125.93 | Mex$475.00 | n/a | 18 |
| Nov ’24 | n/a | Mex$925.71 0% | 18.1% | Mex$1,349.41 | Mex$620.00 | n/a | 17 |
| Oct ’24 | Mex$478.43 | Mex$937.23 +95.9% | 17.6% | Mex$1,308.58 | Mex$601.24 | n/a | 17 |
| Sep ’24 | n/a | Mex$922.26 0% | 15.0% | Mex$1,265.22 | Mex$683.90 | n/a | 17 |
| Aug ’24 | Mex$662.50 | Mex$898.15 +35.6% | 20.2% | Mex$1,256.82 | Mex$509.52 | Mex$591.47 | 17 |
| Jul ’24 | n/a | Mex$928.94 0% | 20.3% | Mex$1,304.24 | Mex$528.75 | n/a | 17 |
| Jun ’24 | n/a | Mex$928.94 0% | 20.3% | Mex$1,304.24 | Mex$528.75 | n/a | 17 |
| May ’24 | Mex$444.00 | Mex$1,003.91 +126.1% | 25.1% | Mex$1,628.47 | Mex$610.67 | n/a | 16 |
| Apr ’24 | n/a | Mex$1,003.91 0% | 25.1% | Mex$1,628.47 | Mex$610.67 | Mex$293.83 | 16 |
| Mar ’24 | n/a | Mex$1,047.06 0% | 20.1% | Mex$1,620.07 | Mex$662.76 | Mex$360.00 | 16 |
| Feb ’24 | Mex$591.33 | Mex$1,259.42 +113.0% | 19.0% | Mex$1,701.79 | Mex$696.19 | n/a | 16 |
| Jan ’24 | n/a | Mex$1,373.94 0% | 16.1% | Mex$1,781.77 | Mex$989.87 | n/a | 15 |
| Dec ’23 | n/a | Mex$1,529.80 0% | 14.2% | Mex$1,921.96 | Mex$970.69 | n/a | 15 |
| Nov ’23 | Mex$972.48 | Mex$1,831.32 +88.3% | 21.4% | Mex$2,563.59 | Mex$986.00 | n/a | 15 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.